Financhill
Sell
9

CDT Quote, Financials, Valuation and Earnings

Last price:
$4.05
Seasonality move :
-30.43%
Day range:
$3.25 - $4.68
52-week range:
$3.25 - $4,905.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.03x
Volume:
181.7K
Avg. volume:
164.8K
1-year change:
-99.92%
Market cap:
$2.8M
Revenue:
--
EPS (TTM):
-$237.75

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CDT
Conduit Pharmaceuticals
-- -- -- -- --
IFRX
InflaRx NV
$36.3K -$0.20 256.48% -10.49% $8.92
LENZ
LENZ Therapeutics
-- -$0.32 -- -26.67% $44.63
LIMN
Liminatus Pharma
-- -- -- -- --
MAZE
Maze Therapeutics
-- -$0.63 -- -- $25.00
ORKA
Oruka Therapeutics
-- -$0.48 -- -42.18% $39.50
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CDT
Conduit Pharmaceuticals
$3.48 -- $2.8M -- $0.00 0% --
IFRX
InflaRx NV
$1.85 $8.92 $125.3M -- $0.00 0% 611.13x
LENZ
LENZ Therapeutics
$28.18 $44.63 $793M -- $1.03 0% --
LIMN
Liminatus Pharma
-- -- -- -- $0.00 0% --
MAZE
Maze Therapeutics
$10.28 $25.00 $440.3M -- $0.00 0% --
ORKA
Oruka Therapeutics
$10.95 $39.50 $410M -- $19.36 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CDT
Conduit Pharmaceuticals
-- 2.365 -- --
IFRX
InflaRx NV
-- 4.290 -- 3.85x
LENZ
LENZ Therapeutics
-- 0.772 -- --
LIMN
Liminatus Pharma
-- 0.000 -- --
MAZE
Maze Therapeutics
-- 0.000 -- --
ORKA
Oruka Therapeutics
-- -0.428 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CDT
Conduit Pharmaceuticals
-- -$4M -- -- -- -$4.3M
IFRX
InflaRx NV
-$9.8K -$13.7M -56.78% -56.78% 1207051.66% -$14.8M
LENZ
LENZ Therapeutics
-- -$16.9M -- -- -- -$16.2M
LIMN
Liminatus Pharma
-- -- -- -- -- --
MAZE
Maze Therapeutics
-- -- -- -- -- --
ORKA
Oruka Therapeutics
-- -$25.1M -- -- -- -$20.9M

Conduit Pharmaceuticals vs. Competitors

  • Which has Higher Returns CDT or IFRX?

    InflaRx NV has a net margin of -- compared to Conduit Pharmaceuticals's net margin of -14092.9%. Conduit Pharmaceuticals's return on equity of -- beat InflaRx NV's return on equity of -56.78%.

    Company Gross Margin Earnings Per Share Invested Capital
    CDT
    Conduit Pharmaceuticals
    -- -$19.80 --
    IFRX
    InflaRx NV
    -5376.61% -$0.14 $63.9M
  • What do Analysts Say About CDT or IFRX?

    Conduit Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand InflaRx NV has an analysts' consensus of $8.92 which suggests that it could grow by 381.95%. Given that InflaRx NV has higher upside potential than Conduit Pharmaceuticals, analysts believe InflaRx NV is more attractive than Conduit Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CDT
    Conduit Pharmaceuticals
    0 0 0
    IFRX
    InflaRx NV
    6 1 0
  • Is CDT or IFRX More Risky?

    Conduit Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.572, suggesting its more volatile than the S&P 500 by 57.18%.

  • Which is a Better Dividend Stock CDT or IFRX?

    Conduit Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Conduit Pharmaceuticals pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CDT or IFRX?

    Conduit Pharmaceuticals quarterly revenues are --, which are smaller than InflaRx NV quarterly revenues of -$450. Conduit Pharmaceuticals's net income of -$5.1M is higher than InflaRx NV's net income of -$8.7M. Notably, Conduit Pharmaceuticals's price-to-earnings ratio is -- while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Conduit Pharmaceuticals is -- versus 611.13x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CDT
    Conduit Pharmaceuticals
    -- -- -- -$5.1M
    IFRX
    InflaRx NV
    611.13x -- -$450 -$8.7M
  • Which has Higher Returns CDT or LENZ?

    LENZ Therapeutics has a net margin of -- compared to Conduit Pharmaceuticals's net margin of --. Conduit Pharmaceuticals's return on equity of -- beat LENZ Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CDT
    Conduit Pharmaceuticals
    -- -$19.80 --
    LENZ
    LENZ Therapeutics
    -- -$0.53 --
  • What do Analysts Say About CDT or LENZ?

    Conduit Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand LENZ Therapeutics has an analysts' consensus of $44.63 which suggests that it could grow by 58.39%. Given that LENZ Therapeutics has higher upside potential than Conduit Pharmaceuticals, analysts believe LENZ Therapeutics is more attractive than Conduit Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CDT
    Conduit Pharmaceuticals
    0 0 0
    LENZ
    LENZ Therapeutics
    5 0 0
  • Is CDT or LENZ More Risky?

    Conduit Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LENZ Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock CDT or LENZ?

    Conduit Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENZ Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $1.03 per share. Conduit Pharmaceuticals pays -- of its earnings as a dividend. LENZ Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CDT or LENZ?

    Conduit Pharmaceuticals quarterly revenues are --, which are smaller than LENZ Therapeutics quarterly revenues of --. Conduit Pharmaceuticals's net income of -$5.1M is higher than LENZ Therapeutics's net income of -$14.6M. Notably, Conduit Pharmaceuticals's price-to-earnings ratio is -- while LENZ Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Conduit Pharmaceuticals is -- versus -- for LENZ Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CDT
    Conduit Pharmaceuticals
    -- -- -- -$5.1M
    LENZ
    LENZ Therapeutics
    -- -- -- -$14.6M
  • Which has Higher Returns CDT or LIMN?

    Liminatus Pharma has a net margin of -- compared to Conduit Pharmaceuticals's net margin of --. Conduit Pharmaceuticals's return on equity of -- beat Liminatus Pharma's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CDT
    Conduit Pharmaceuticals
    -- -$19.80 --
    LIMN
    Liminatus Pharma
    -- -- --
  • What do Analysts Say About CDT or LIMN?

    Conduit Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand Liminatus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Conduit Pharmaceuticals has higher upside potential than Liminatus Pharma, analysts believe Conduit Pharmaceuticals is more attractive than Liminatus Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    CDT
    Conduit Pharmaceuticals
    0 0 0
    LIMN
    Liminatus Pharma
    0 0 0
  • Is CDT or LIMN More Risky?

    Conduit Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Liminatus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock CDT or LIMN?

    Conduit Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liminatus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Conduit Pharmaceuticals pays -- of its earnings as a dividend. Liminatus Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CDT or LIMN?

    Conduit Pharmaceuticals quarterly revenues are --, which are smaller than Liminatus Pharma quarterly revenues of --. Conduit Pharmaceuticals's net income of -$5.1M is higher than Liminatus Pharma's net income of --. Notably, Conduit Pharmaceuticals's price-to-earnings ratio is -- while Liminatus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Conduit Pharmaceuticals is -- versus -- for Liminatus Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CDT
    Conduit Pharmaceuticals
    -- -- -- -$5.1M
    LIMN
    Liminatus Pharma
    -- -- -- --
  • Which has Higher Returns CDT or MAZE?

    Maze Therapeutics has a net margin of -- compared to Conduit Pharmaceuticals's net margin of --. Conduit Pharmaceuticals's return on equity of -- beat Maze Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CDT
    Conduit Pharmaceuticals
    -- -$19.80 --
    MAZE
    Maze Therapeutics
    -- -- --
  • What do Analysts Say About CDT or MAZE?

    Conduit Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand Maze Therapeutics has an analysts' consensus of $25.00 which suggests that it could grow by 143.19%. Given that Maze Therapeutics has higher upside potential than Conduit Pharmaceuticals, analysts believe Maze Therapeutics is more attractive than Conduit Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CDT
    Conduit Pharmaceuticals
    0 0 0
    MAZE
    Maze Therapeutics
    3 0 0
  • Is CDT or MAZE More Risky?

    Conduit Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Maze Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock CDT or MAZE?

    Conduit Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Maze Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Conduit Pharmaceuticals pays -- of its earnings as a dividend. Maze Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CDT or MAZE?

    Conduit Pharmaceuticals quarterly revenues are --, which are smaller than Maze Therapeutics quarterly revenues of --. Conduit Pharmaceuticals's net income of -$5.1M is higher than Maze Therapeutics's net income of --. Notably, Conduit Pharmaceuticals's price-to-earnings ratio is -- while Maze Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Conduit Pharmaceuticals is -- versus -- for Maze Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CDT
    Conduit Pharmaceuticals
    -- -- -- -$5.1M
    MAZE
    Maze Therapeutics
    -- -- -- --
  • Which has Higher Returns CDT or ORKA?

    Oruka Therapeutics has a net margin of -- compared to Conduit Pharmaceuticals's net margin of --. Conduit Pharmaceuticals's return on equity of -- beat Oruka Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CDT
    Conduit Pharmaceuticals
    -- -$19.80 --
    ORKA
    Oruka Therapeutics
    -- -$0.40 --
  • What do Analysts Say About CDT or ORKA?

    Conduit Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand Oruka Therapeutics has an analysts' consensus of $39.50 which suggests that it could grow by 260.73%. Given that Oruka Therapeutics has higher upside potential than Conduit Pharmaceuticals, analysts believe Oruka Therapeutics is more attractive than Conduit Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CDT
    Conduit Pharmaceuticals
    0 0 0
    ORKA
    Oruka Therapeutics
    7 0 0
  • Is CDT or ORKA More Risky?

    Conduit Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oruka Therapeutics has a beta of 0.252, suggesting its less volatile than the S&P 500 by 74.841%.

  • Which is a Better Dividend Stock CDT or ORKA?

    Conduit Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oruka Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $19.36 per share. Conduit Pharmaceuticals pays -- of its earnings as a dividend. Oruka Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CDT or ORKA?

    Conduit Pharmaceuticals quarterly revenues are --, which are smaller than Oruka Therapeutics quarterly revenues of --. Conduit Pharmaceuticals's net income of -$5.1M is higher than Oruka Therapeutics's net income of -$21M. Notably, Conduit Pharmaceuticals's price-to-earnings ratio is -- while Oruka Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Conduit Pharmaceuticals is -- versus -- for Oruka Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CDT
    Conduit Pharmaceuticals
    -- -- -- -$5.1M
    ORKA
    Oruka Therapeutics
    -- -- -- -$21M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?
UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?

Parcel delivery giant UPS (NYSE:UPS) has seen its fair share…

Where Will Coinbase Stock Be in 5 Years?
Where Will Coinbase Stock Be in 5 Years?

If you’ve been anywhere near the crypto world over the…

How High Will Planet Labs Stock Go in 2025?
How High Will Planet Labs Stock Go in 2025?

Today we dive into Planet Labs (NYSE: PL), the satellite…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 38x

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 45x

Sell
33
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Buy
55
SBET alert for May 27

SharpLink Gaming [SBET] is up 480.36% over the past day.

Buy
60
MRUS alert for May 27

Merus NV [MRUS] is down 5.59% over the past day.

Buy
57
RGC alert for May 27

Regencell Bioscience Holdings [RGC] is down 10.61% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock